- Home
- BBIO vs CORT Comparison
BBIO vs CORT Comparison
Compare BBIO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- CORT
- Stock Information
- Founded
- BBIO 2015
- CORT 1998
- Country
- BBIO United States
- CORT United States
- Employees
- BBIO N/A
- CORT N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- CORT Health Care
- Exchange
- BBIO Nasdaq
- CORT Nasdaq
- Market Cap
- BBIO 9.4B
- CORT 8.8B
- IPO Year
- BBIO 2019
- CORT N/A
- Fundamental
- Price
- BBIO $55.32
- CORT $89.45
- Analyst Decision
- BBIO Strong Buy
- CORT Strong Buy
- Analyst Count
- BBIO 16
- CORT 4
- Target Price
- BBIO $64.44
- CORT $139.00
- AVG Volume (30 Days)
- BBIO 2.0M
- CORT 940.0K
- Earning Date
- BBIO 11-11-2025
- CORT 10-29-2025
- Dividend Yield
- BBIO N/A
- CORT N/A
- EPS Growth
- BBIO N/A
- CORT N/A
- EPS
- BBIO N/A
- CORT 1.11
- Revenue
- BBIO $235,812,000.00
- CORT $716,080,000.00
- Revenue This Year
- BBIO $115.46
- CORT $30.77
- Revenue Next Year
- BBIO $65.03
- CORT $37.75
- P/E Ratio
- BBIO N/A
- CORT $79.36
- Revenue Growth
- BBIO 7.62
- CORT 25.71
- 52 Week Low
- BBIO $21.72
- CORT $42.01
- 52 Week High
- BBIO $55.32
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- BBIO 59.91
- CORT 77.61
- Support Level
- BBIO $52.97
- CORT $82.70
- Resistance Level
- BBIO $55.13
- CORT $90.71
- Average True Range (ATR)
- BBIO 1.58
- CORT 2.28
- MACD
- BBIO 0.16
- CORT 0.72
- Stochastic Oscillator
- BBIO 84.41
- CORT 96.01
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.